Morgan Stanley Issues Positive Forecast for Thermo Fisher Scientific (NYSE:TMO) Stock Price

Thermo Fisher Scientific (NYSE:TMO) had its price target hoisted by Morgan Stanley from $656.00 to $670.00 in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The firm currently has an overweight rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, TD Cowen lifted their target price on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $602.35.

Thermo Fisher Scientific Stock Down 0.8%

Shares of Thermo Fisher Scientific stock opened at $580.27 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $610.97. The stock has a 50-day moving average price of $552.97 and a 200 day moving average price of $482.58. The company has a market cap of $218.01 billion, a P/E ratio of 33.52, a P/E/G ratio of 3.27 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the firm earned $5.28 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts expect that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the sale, the executive vice president owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 51,800 shares of company stock worth $30,003,027. Corporate insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several hedge funds have recently modified their holdings of TMO. Swiss Life Asset Management Ltd grew its holdings in shares of Thermo Fisher Scientific by 4.7% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 45,080 shares of the medical research company’s stock worth $21,865,000 after purchasing an additional 2,007 shares in the last quarter. Groupama Asset Managment lifted its position in Thermo Fisher Scientific by 58.9% in the third quarter. Groupama Asset Managment now owns 245,016 shares of the medical research company’s stock worth $118,838,000 after purchasing an additional 90,854 shares during the period. Investment Research Partners LLC acquired a new stake in Thermo Fisher Scientific during the third quarter worth $311,000. Cambria Investment Management L.P. acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $723,000. Finally, KERR FINANCIAL PLANNING Corp bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $38,000. 89.23% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.